Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease.
OBJECTIVE
To determine the prevalence of occult pre-malignant or malignant uterine pathology at the time of laparoscopic surgery with open power morcellation for benign gynecologic disease.


METHODS
The present multicenter, retrospective cohort study included women who underwent open power morcellation for benign indications between January 1, 2007, and February 28, 2014, at three academic medical centers in the USA. The primary outcome was pre-malignant or malignant pathology at the time of open power morcellation, and was determined from the patients' pathology reports.


RESULTS
During the study period, 1214 women underwent open power morcellation for benign indications. Similar preoperative characteristics were observed between patients with normal pathology and those with pre-malignant or malignant uterine pathology, including body mass index, parity, hypertension, diabetes, breast cancer, and smoking (all P>0.129). Among patients who underwent open power morcellation, 14 (1.2%) had occult pre-malignant or malignant pathology; 5 (0.4%) women had endometrial adenocarcinoma and 1 (0.1%) had low-grade endometrial stromal sarcoma. There were eight patients with malignant pathology who underwent additional surgical exploration and were disease free at their final clinical visit, with a median follow-up time of 42.0 months (interquartile range 5.0-62.0 months).


CONCLUSIONS
Endometrial adenocarcinoma and low-grade endometrial stromal sarcoma were rare in the present study and there were no reports of leiomyosarcoma.
Department of Obstetrics and Gynecology, Mount Auburn Hospital, Harvard Medical School affiliate, Cambridge, MA, USA.|Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA.
Emily C
EC
Von Bargen
Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA.
Cara L
CL
Grimes
Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA.
Kavita
K
Mishra
Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
Rui
R
Wang
Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
Miriam J
MJ
Haviland
Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
Michele R
MR
Hacker
Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA.
Joseph A
JA
Carnevale
Touro College of Osteopathic Medicine, New York, NY, USA.
Alyssa J
AJ
Estes
Department of Obstetrics and Gynecology, Mount Auburn Hospital, Harvard Medical School affiliate, Cambridge, MA, USA.|Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA.
Eman A
EA
Elkadry
D000230:Adenocarcinoma / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D000328:Adult; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000473:pathology / Q000601:surgery; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D000069577:Morcellation; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D015995:Prevalence; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D063186:Uterine Myomectomy; D014594:Uterine Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D016387:Women's Health
Fibroids; Hysterectomy; Morcellation; Myomectomy; Uterine malignancy